Clinical potential of [18F]FET PET in patients with circumscribed astrocytic glioma
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07654-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Jan-Michael Werner und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Astrocytoma, Tyrosine, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
Purpose
To investigate the clinical potential of O -(2-[ 18 F]fluoroethyl)-L-tyrosine ([ 18 F]FET) PET imaging in the management of circumscribed astrocytic gliomas (CAG), a rare glioma subtype with limited imaging data.
Methods
We retrospectively identified adult CAG patients who underwent [ 18 F]FET PET imaging (i) before diagnosis, (ii) at suspected relapse, or (iii) for response assessment at three institutions. Maximum and mean tumor-to-brain ratios (TBR max , TBR mean ) and metabolic tumor volumes were assessed according to the PET RANO 1.0 criteria. Diagnostic performance in differentiating treatment-related changes from tumor relapse was evaluated using ROC analysis and Fisher’s exact test.
Results
We evaluated 79 [ 18 F]FET PET scans of 42 patients, including nine (21%) with actionable molecular targets. Measurable [ 18 F]FET uptake was observed in 65% of WHO grade 1 and 100% of WHO grade 2 and 3 CAG. TBR values were significantly higher in WHO grade 2 and 3 CAG than in pilocytic astrocytomas ( P < 0.01), but showed no difference based on molecular target status ( P > 0.05). In 5 of 11 patients (45%), treatment response assessment by PET RANO 1.0 differed from MRI. Treatment-related changes were confirmed in 12 patients (43%). In CAG WHO grades 2 or 3, the accuracy of [ 18 F]FET PET to identify treatment-related changes was 82% using single PET scans and 100% using serial PET imaging ( P < 0.05). Conclusions [ 18 F]FET PET can contribute to clinical management of patients with CAG by detecting measurable disease, differentiating treatment-related changes from tumor progression, and showing potential in treatment response assessment through longitudinal imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Neurology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
- Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
ORCID-Profile: Jan-Michael Werner, Maximilian J Mair, Michael M Wollring, Isabelle Stetter, Hannah C Puhr, Anna S Berghoff, Georg Widhalm, Louisa von Baumgarten, Felix M Mottaghy, Philipp Lohmann, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks, Nathalie L Albert, Matthias Preusser
Förderung
- Medical University of Vienna
Zitieren
APA
Werner, J. M., Mair, M. J., Wollring, M. M., Barci, E., Stetter, I., Puhr, H. C., Tscherpel, C., Stoffels, G., Hainfellner, J. A., Berghoff, A. S., Sunder-Plassmann, V., Widhalm, G., Eckert, F., Kasprian, G., Nakuz, T. S., Beck, A., Harter, P. N., von Baumgarten, L., Thon, N., …, & Preusser, M. (2026). Clinical potential of [18F]FET PET in patients with circumscribed astrocytic glioma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07654-9
Vancouver
Werner JM, Mair MJ, Wollring MM, Barci E, Stetter I, Puhr HC, et al. Clinical potential of [18F]FET PET in patients with circumscribed astrocytic glioma. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07654-9
BibTeX
@article{Werner2026,
author = {Werner, Jan-Michael and Mair, Maximilian J and Wollring, Michael M and Barci, Enio and Stetter, Isabelle and Puhr, Hannah C and Tscherpel, Caroline and Stoffels, Gabriele and Hainfellner, Johannes A and Berghoff, Anna S and Sunder-Plassmann, Vincent and Widhalm, Georg and Eckert, Franziska and Kasprian, Gregor and Nakuz, Thomas S and Beck, Alexander and Harter, Patrick N and von Baumgarten, Louisa and Thon, Niklas and Schönecker, Stephan and Forbrig, Robert and Mottaghy, Felix M and Lohmann, Philipp and Fink, Gereon R and Langen, Karl-Josef and Galldiks, Norbert and Albert, Nathalie L and Preusser, Matthias},
title = {Clinical potential of [18F]FET PET in patients with circumscribed astrocytic glioma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07654-9}
}
EUVIMED